Evidence map›Paper›PMID 35913637›Full record

Observational studyJournal of cancer research and clinical oncology2023

Prognostic utility of SOX2, STAT3, and CD44

Felipe Dubourcq de Barros, Leuridan Cavalcante Torres, Carolline Araujo, Felipe da Silva Marinho, Beatriz Cavalcanti Dubourcq, Luís Cavalcanti Dubourcq, Gustavo Cardoso Guimarães

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Felipe Dubourcq de BarrosHospital de Câncer de Pernambuco, Av Cruz Cabuga 1597 Santo Amaro, Recife, Pernambuco, 50040000, Brazil. felipedubourcq@outlook.com.ORCID http://orcid.org/0000-0002-7881-3322
Leuridan Cavalcante TorresInstituto de Medicina Integrada de Pernambuco, Recife, Pernambuco, Brazil.ORCID http://orcid.org/0000-0003-3517-6615
Carolline AraujoFaculdade de Medicina de Olinda, Olinda, Pernambuco, Brazil.ORCID http://orcid.org/0000-0002-7651-9429
Felipe da Silva MarinhoHospital de Câncer de Pernambuco, Av Cruz Cabuga 1597 Santo Amaro, Recife, Pernambuco, 50040000, Brazil.
Beatriz Cavalcanti DubourcqHospital de Câncer de Pernambuco, Av Cruz Cabuga 1597 Santo Amaro, Recife, Pernambuco, 50040000, Brazil.ORCID http://orcid.org/0000-0003-3310-4650
Luís Cavalcanti DubourcqHospital de Câncer de Pernambuco, Av Cruz Cabuga 1597 Santo Amaro, Recife, Pernambuco, 50040000, Brazil.ORCID http://orcid.org/0000-0001-8622-6892
Gustavo Cardoso GuimarãesAC Camargo Cancer Center, São Paulo, Brazil.ORCID http://orcid.org/0000-0002-1317-2114
Hospital de Câncer de Pernambuco · BRAC Camargo Hospital · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePenile cancer has a high incidence in developing countries. The standard treatment is removal of the primary tumor and, when necessary, inguinal lymphadenectomy. Currently, the most important prognostic factor is lymph node disease, however, the available staging methods are inaccurate, and the high morbidity rate of lymphadenectomy has stimulated the study of predictive biomarkers of lymph node metastasis for selecting the patients who need lymphadenectomy. SOX2, STAT3 and CD44

methodsThis observational, prospective, translational study included 34 men and investigated the expression of SOX2, STAT3, CD24+, and CD44+ in tumor tissue by flow cytometry.

resultsThe median age of the 38 evaluated patients with penile cancer was 61 (37-80) years. Most patients presented a tumor located on the glans penis (82.3%), with the usual histological type (79.4%) and 61.7% of patients presented stage pT2. No metastasis was found in 85.3% of patients. The expression of SOX2, STAT3 and CD44

conclusionSOX2, STAT3 and CD44

Indexed as

Carcinoma, Squamous CellPenile NeoplasmsAgedAged, 80 and overBiomarkersCD24 AntigenHumansHyaluronan ReceptorsMaleMiddle AgedPrognosisProspective StudiesSOXB1 Transcription FactorsSTAT3 Transcription FactorTumor MicroenvironmentBiomarkersCD24 AntigenCD24 protein, humanCD44 protein, humanHyaluronan ReceptorsSOX2 protein, humanSOXB1 Transcription FactorsSTAT3 protein, humanSTAT3 Transcription FactorBiomarkersPenile cancerTranscription factor SOX2Transcription factor STAT3Translational study

Identifiers

PMID35913637
PMCPMC11796821
OpenAlexW4289341896

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.